Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers
- 30 June 2007
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 29 (6) , 1040-1056
- https://doi.org/10.1016/j.clinthera.2007.06.012
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Multivariate framework of the Brief Questionnaire of Smoking UrgesDrug and Alcohol Dependence, 2007
- Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking CessationJournal of Medicinal Chemistry, 2005
- Revealing the multidimensional framework of the Minnesota nicotine withdrawal scaleCurrent Medical Research and Opinion, 2005
- Outcome criteria in smoking cessation trials: proposal for a common standardAddiction, 2005
- Measures of abstinence in clinical trials: issues and recommendationsNicotine & Tobacco Research, 2003
- Effects of gender on relapse prevention in smokers treated with bupropion SRAmerican Journal of Preventive Medicine, 2002
- Biochemical verification of tobacco use and cessationNicotine & Tobacco Research, 2002
- Nicotine–mecamylamine treatment for smoking cessation: The role of pre-cessation therapy.Experimental and Clinical Psychopharmacology, 1998
- Nicotine dependence versus smoking prevalence: comparisons among countries and categories of smokersTobacco Control, 1996
- The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance QuestionnaireBritish Journal of Addiction, 1991